SEX STEROIDS AND MAMMOGRAM DENSITY IN THE POSTMENOPAUSE

描述：(改编自《调查者摘要》)流行病学研究 发现乳房X光检查密度增加是患乳腺癌的独立危险因素 乳腺癌与乳房X线摄影密度相关的风险大小 大于与几乎所有其他已知风险因素有关的风险 乳腺癌。本申请重点解决了3个主要问题：1)是 绝经后妇女内源性类固醇激素水平与 乳腺X光摄影密度；2)使用绝经后雌激素和 雌激素/孕激素治疗增加了乳房X光照相密度；3) 雌酮治疗后的血清雌酮水平 绝经后激素治疗可以预测钼靶密度的变化？至 解决这些问题，所进行的乳房X光检查的密度 在绝经后雌激素/孕激素干预(PEPI)试验期间 使用基于计算机的阈值技术来确定。佩皮是一个 马结合雌激素的3年随机安慰剂对照试验 (CEE)与CEE加3种孕激素方案中的一种，共招募了875人 绝经后妇女45岁--基线。已作为部分收集的数据 将在这个项目中使用的Pepi将包括：内源性性行为 基线类固醇、PEPI治疗分配、雌酮血清水平 治疗中，和必要的协变量。该项目将持续3年， 在3个地点举行：加州大学洛杉矶分校、南加州大学和鲍曼·格雷。具体目标是 到：1)测量在基线和12)时进行的乳房X光检查的密度 月；2)确定基线乳房X光检查密度是否与 与内源性类固醇水平的关系；3)量化 乳房X光照相密度的变化和对治疗的坚持；以及4)确定 变化密度是否与血清雌酮水平相关 作为荷尔蒙治疗的结果。通过评估乳房X光照片中的密度变化 使用这种基于计算机的方法，该方法以前已链接到 乳腺癌风险的量化增加，有可能评估 激素的使用可以预测风险增加的程度。这个 调查人员表示，这可能是一系列 进行调查，以确定哪些妇女的风险较高 绝经后补充激素导致的乳房毒性。

DESCRIPTION: (Adapted from Investigator's Abstract) Epidemiologic studies find that increased mammographic density is an independent risk factor for breast cancer and the magnitude of risk associated with mammographic density is greater than that associated with almost all other known risk factors for breast cancer. This application focuses on 3 major questions: 1) are endogenous levels of sex steroids in postmenopausal women related to mammographic density; 2) does treatment with postmenopausal estrogen and estrogen/progestin therapy increase mammographic density; and 3) do the serum levels of estrone achieved as a result of treatment with postmenopausal hormone therapy predict change in mammographic density? To address these questions, the amount of density of mammograms performed during the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial will be determined using a computer-based threshold technique. PEPI was a 3-year, randomized placebo controlled trial of conjugated equine estrogens (CEE) vs. CEE plus one of 3 progestin regimens, which enrolled 875 postmenopausal women aged 45-64 at baseline. Data already collected as part of PEPI that will be used in this project will include: endogenous sex steroids at baseline, PEPI treatment assignment, estrone serum levels on-treatment, and necessary covariates. The project will last 3 years and take place at 3 sites: UCLA, USC, and Bowman Gray. The specific aims are to: 1) measure the density of mammograms performed at baseline and 12 months; 2) determine whether baseline mammographic density is associated with endogenous levels of sex steroids; 3) quantify the relation between change in mammographic density and adherence to treatments; and 4) determine whether changes density are associated with serum levels of estrone achieved as a result of hormone therapy. By assessing density changes in mammograms with this computer-based method, which has been previously linked to a quantified increase in risk of breast cancer, it may be possible to assess how much of a risk-increase would be predicted by hormone use. The investigators state that this may serve as the first in a series of investigations that would allow identification of those women at higher risk of developing breast toxicity from postmenopausal supplemental hormone use.